LEADER 02140nam  2200541Ia 450 
001 9910783331003321
005 20230617011608.0
010   $a0-309-54976-0
035   $a(CKB)1000000000030478
035   $a(EBL)3377918
035   $a(SSID)ssj0000672895
035   $a(PQKBManifestationID)11453482
035   $a(PQKBTitleCode)TC0000672895
035   $a(PQKBWorkID)10642671
035   $a(PQKB)11173260
035   $a(MiAaPQ)EBC3377918
035   $a(Au-PeEL)EBL3377918
035   $a(CaPaEBR)ebr10078111
035   $a(OCoLC)923274023
035   $a(EXLCZ)991000000000030478
100   $a20050524d2005      uy             0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aFederal agency roles in cancer drug development from preclinical research to new drug approval$b[electronic resource] $ethe National Cancer Institute and the Food and Drug Administration /$fJoseph P. Newhouse, John Mendelsohn, Hellen Gelband and Roger Herdman
205   $a3rd ed.
210   $aWashington, D.C. $cNational Academy Press$dc2005
215   $a1 online resource (69 p.)
300   $aDescription based upon print version of record.
311   $a0-309-09639-1 
327   $a""FRONT MATTER""; ""Table of Contents""; ""1  SCIENTIFIC RATIONALE""; ""2  THE NATIONAL CANCER INSTITUTE""; ""3  THE FOOD AND DRUG ADMINISTRATION""; ""4  SUMMARY: THE ROLES OF THE NCI AND FDA IN DEVELOPING ANTICANCER AGENTS""; ""REFERENCES""; ""ACRONYMS AND ABBREVIATIONS""
606   $aAntineoplastic agents$xDevelopment
606   $aPublic administration$zUnited States
615  0$aAntineoplastic agents$xDevelopment.
615  0$aPublic administration
700   $aNewhouse$b Joseph P$0145731
701   $aMendelsohn$b John M$01488935
701   $aGelband$b Hellen$01485113
701   $aHerdman$b Roger$01485067
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910783331003321
996   $aFederal agency roles in cancer drug development from preclinical research to new drug approval$93709365
997   $aUNINA